Form 4 for MRNA Moderna
Accepted 2022-02-11 00:00:00 ET · period of report 2022-02-09 · accession 0001127602-22-004566 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-11 | 2022-02-09 | MRNA | Meline David W | CFO | M - OptEx | $0.00 | +1,392 | 3,010 | +86% | $0 |
| D | 2022-02-11 | 2022-02-10 | MRNA | Meline David W | CFO | S - Sale+OE | $158.89 | -619 | 2,391 | -21% | -$98.4K |
| D | 2022-02-11 | 2022-02-09 | MRNA | Meline David W | CFO | M - OptEx | $0.00 | -1,392 | 4,178 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-09 | M | A | 1,392 | $0.00 | 3,010 | D | — | — | (F2) Includes 118 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on November 30, 2021. |
| 2 | Common | Common Stock | 2022-02-10 | S | D | 619 | $158.89 | 2,391 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2022-02-09 | M | D | 1,392 | $0.00 | 4,178 | D | $0.00 · — to — | 1,392 Common Stock | (F4) 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |